Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 7
2015 8
2016 6
2017 2
2019 6
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year
Filters applied: . Clear all
Page 1
Cluster-randomized crossover trial of chlorhexidine-alcohol versus iodine-alcohol for prevention of surgical-site infection (SKINFECT trial).
Charehbili A, Koek MBG, de Mol van Otterloo JCA, Bronkhorst MWGA, van der Zwaal P, Thomassen B, Waasdorp EJ, Govaert JA, Bosman A, van den Bremer J, Ploeg AJ, Putter H, Meijs AP, van de Velde CJH, van Gijn W, Swijnenburg RJ. Charehbili A, et al. BJS Open. 2019 May 20;3(5):617-622. doi: 10.1002/bjs5.50177. eCollection 2019 Oct. BJS Open. 2019. PMID: 31592513 Free PMC article. Clinical Trial.
[A pulsatile mass on the forehead after a fall].
Schröder LBW, Charehbili A. Schröder LBW, et al. Among authors: charehbili a. Ned Tijdschr Geneeskd. 2019 May 24;163:D3835. Ned Tijdschr Geneeskd. 2019. PMID: 31166092 Dutch.
Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer.
Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, Fruytier SE, Meershoek-Klein Kranenbarg E, Kloet S, van der Burg B, Martens JWM, Sims AH, Turnbull AK, Dixon JM, Verhaegh W, Kroep JR, van de Velde CJH, van de Stolpe A. Inda MA, et al. Among authors: charehbili a. Mol Cancer Ther. 2020 Feb;19(2):680-689. doi: 10.1158/1535-7163.MCT-19-0318. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727690 Free article.
Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer.
Hagenaars SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Pijl H, Putter H, Tollenaar RAEM, Kroep JR, Mesker WE; Dutch Breast Cancer Research Group (BOOG). Hagenaars SC, et al. Among authors: charehbili a. Int J Cancer. 2021 Sep 1;149(5):1181-1188. doi: 10.1002/ijc.33700. Epub 2021 Jun 5. Int J Cancer. 2021. PMID: 34043821
Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group. de Groot S, et al. Among authors: charehbili a. Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3. Breast Cancer Res. 2016. PMID: 26738606 Free PMC article. Clinical Trial.
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Pijl H, Charehbili A, van de Ven S, Smit VTHBM, Meershoek-Klein Kranenbarg E, Heijns JB, van Warmerdam LJC, Kessels LW, Dercksen MW, Pepels MJAE, van Laarhoven HWM, Vriens BEPJ, Putter H, Fiocco M, Liefers GJ, van der Hoeven JJM, Nortier JWR, Kroep JR; Dutch Breast Cancer Research Group. de Groot S, et al. Among authors: charehbili a. Breast Cancer Res. 2019 Aug 28;21(1):97. doi: 10.1186/s13058-019-1180-6. Breast Cancer Res. 2019. PMID: 31455425 Free PMC article.
26 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page